Longport Stock

Longport FCF/Debt

The Free Cash Flow to Debt Ratio of Longport (LPTI) as of Aug 15, 2026 is -22.53 %. In the previous year, Free Cash Flow to Debt Ratio was -47.77 % — a change of -52.83% (higher).

FCF/Debt

-22.53 %

YoY

-52.83%

Last updated:

Free Cash Flow to Debt Ratio of Longport is 2026 -22.53 % . Free Cash Flow to Debt Ratio of Longport was 2025 -47.77 % . It decreases by -52.83% higher compared to the previous year.
Access this data via the Eulerpool API

Longport Stock analysis

What does Longport do? Longport Inc is a US-based company specializing in the development, manufacturing, and marketing of medical devices. It was founded in 1998 by a group of engineers and businesspeople with a vision to create devices that make medical treatments more effective and safer. The business model of Longport Inc is based on providing customized solutions for medical applications. The company offers a wide range of products and services focusing on various medical fields such as radiology, urology, neurology, gastroenterology, and cardiology. Another focus is on developing products for the treatment of vascular diseases. The company follows a customer-oriented philosophy tailored to the needs of its customers. It works closely with hospitals and other healthcare facilities and has built partnerships with medical device companies worldwide. Longport Inc is headquartered in New Jersey, USA, and has branches in Europe and Asia. It employs a wide range of professionals including engineers, scientists, salespeople, and managers. In terms of its various product divisions, Longport Inc is best known for its medical imaging products. The company has developed a range of products that contribute to improving the accuracy and effectiveness of X-ray and ultrasound images. These include image processing software, detectors, and other accessories. In urology, Longport Inc has developed a wide range of products supporting the diagnosis and treatment of prostate diseases. This includes devices such as the transrectal ultrasound probe and the prostate biopsy needle. In neurology, the company offers devices for the diagnosis and treatment of brain injuries and diseases. These range from stereotactic devices used for deep brain stimulation procedures to devices used for measuring brain waves. In the field of gastroenterology, Longport Inc provides products for the diagnosis and treatment of gastrointestinal inflammation, as well as for the treatment of stomach ulcers and other stomach issues. Finally, the company also develops products for other medical applications beyond its core areas. These include devices for monitoring blood pressure, measuring blood glucose levels, and treating heart diseases. Over the years, Longport Inc has received several awards for its innovative products and exceptional achievements in the field of medical device manufacturing. The company is committed to continuing to develop innovative solutions for the medical industry to improve patient treatment worldwide. Longport is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Longport stock

Free Cash Flow to Debt Ratio of Longport is -22.53 % in 2026.

Free Cash Flow to Debt Ratio of Longport changed from -47.77 % to -22.53 %, representing a -52.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Longport since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Longport with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Longport

All Key Metrics — Longport